Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma
Open Access
- 15 April 1987
- Vol. 59 (8) , 1470-1474
- https://doi.org/10.1002/1097-0142(19870415)59:8<1470::aid-cncr2820590813>3.0.co;2-k
Abstract
Clinicopathologic correlations were made in 50 patients with follicular large cell (FLC) lymphoma to better define the influence of a variety of clinical and pathologic features on survival and the potential for continuous freedom from disease. The 5- and 10-year actuarial survivals for the entire group of patients are 77% and 63%, respectively, but disease-free survival is only 46% at 5 years and 22% at 10 years. No significant survival differences were found with various treatment approaches, although a single relapse occurred after 3 years among patients treated with modern combination chemotherapy containing doxorubicin. Median survivals of approximately 10 years despite recurrent disease are characteristic of the majority of follicular lymphomas. Furthermore, the reproducibility of cytologic diagnosis among follicular lymphomas is known to be variable. At this time, it is unclear whether intensive chemotherapy will cure a significant number of FLC patients or novel approaches are necessary as for the other follicular lymphomas.This publication has 25 references indexed in Scilit:
- Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities.Journal of Clinical Oncology, 1985
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982
- Nodular histiocytic lymphoma:Factors influencing prognosis and implications for aggressive chemotherapyCancer, 1982
- The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiationBlood, 1981
- Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survivalBlood, 1980
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976
- ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASEThe Lancet, 1975
- Immunologic characterization of human malignant lymphomasCancer, 1974
- Non-hodgkin's lymphomas iv. clinicopathologic correlation in 405 casesCancer, 1973
- Follicular lymphoma.A re-evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 casesCancer, 1956